Transaction · 0001209191-24-000316

Wagner Paul A.

Wagner Paul A., SR, reported a transaction classified as exercise at Forte Biosciences, Inc. involving 31250.000000 shares for an estimated $0.00. Reported holdings after the transaction were 1854486.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

exerciseSEC transaction code MSR
FBRXForte Biosciences, Inc.
Filing timeJan 03
Trade dateJan 01, 2024
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
—
Pre-filing
1mo ago1w ago1d ago
Returns since
7d30d90d180d1y

FBRX price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
FBRX since 2024-01-03Filed 974 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
exercise
Code M
Identifier
0001209191-24-000316
Common Stock
Transaction date
Jan 01, 2024
Filed Jan 03, 2024, 04:01 PM · 2d delay
Shares
31.2k sh
$0 per share
Estimated value
$0
Computed from shares × price
Holdings after
1.85M sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Direct Ownership
+10score
Filing-only score

+10

Compact filing score computed from stored Form 4 facts. Version v1.

Positive filing signal

This filing has a modest positive filing-only score. Treat it as a useful flag for review, not as a buy signal.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

See Remarks

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock.

  2. F2

    On January 1, 2024, the Reporting Person's RSUs vested. The closing price of Forte Biosciences, Inc.'s Common Stock on December 29, 2023 was the settlement price used to calculate the shares withheld.…

  3. F3

    Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to t…

Original filing · 0001209191-24-000316
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

FBRX